The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Overview of the role of non-covalent BTK inhibitors in the era of covalent BTK inhibitors
Fateeha Furqan, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the role of non-covalent BTK inhibitors (BTKi), such as pirtobrutinib, in the era of covalent BTKi. Pirtobrutinib is highly selective and, therefore, has fewer side effects than covalent BTKis, resulting in a lower rate of cardiac toxicity. Additionally, non-covalent BTKi act differently on the BTK enzyme, meaning activity can be seen in patients who did not respond to or developed resistance to covalent BTKis. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
